Max Parmar

649 total citations
22 papers, 354 citations indexed

About

Max Parmar is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Reproductive Medicine. According to data from OpenAlex, Max Parmar has authored 22 papers receiving a total of 354 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pulmonary and Respiratory Medicine, 6 papers in Radiology, Nuclear Medicine and Imaging and 6 papers in Reproductive Medicine. Recurrent topics in Max Parmar's work include Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Max Parmar is often cited by papers focused on Prostate Cancer Treatment and Research (10 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Ovarian cancer diagnosis and treatment (5 papers). Max Parmar collaborates with scholars based in United Kingdom, United States and Australia. Max Parmar's co-authors include RJ Stephens, Jan P. van Meerbeeck, R L Souhami, Sarah Burdett, Jean‐Pierre Pignon, D. Johnson, A. Aupérin, C. Le Péchoux, Jayne F. Tierney and R. Arriagada and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

Max Parmar

22 papers receiving 343 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Max Parmar United Kingdom 9 180 165 63 42 41 22 354
A Stone United Kingdom 8 126 0.7× 134 0.8× 54 0.9× 14 0.3× 35 0.9× 22 325
Robin Schaffar Switzerland 10 126 0.7× 196 1.2× 64 1.0× 11 0.3× 33 0.8× 19 338
Sennett K. Kim United States 8 343 1.9× 79 0.5× 58 0.9× 30 0.7× 70 1.7× 13 499
Jacopo Giuliani Italy 12 194 1.1× 206 1.2× 48 0.8× 14 0.3× 39 1.0× 76 391
Ragheed Al-Mufti United Kingdom 12 55 0.3× 89 0.5× 96 1.5× 21 0.5× 28 0.7× 28 370
Melissa D. Curtis United States 6 217 1.2× 258 1.6× 78 1.2× 6 0.1× 45 1.1× 8 427
Elizabeth L. Strevel Canada 9 82 0.5× 140 0.8× 20 0.3× 20 0.5× 112 2.7× 16 410
Paul You United States 6 191 1.1× 241 1.5× 94 1.5× 5 0.1× 42 1.0× 8 412
Carmela Caballero Belgium 10 140 0.8× 164 1.0× 84 1.3× 7 0.2× 57 1.4× 33 357
Rachel Dear Australia 12 137 0.8× 229 1.4× 77 1.2× 8 0.2× 57 1.4× 31 474

Countries citing papers authored by Max Parmar

Since Specialization
Citations

This map shows the geographic impact of Max Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Max Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Max Parmar more than expected).

Fields of papers citing papers by Max Parmar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Max Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Max Parmar. The network helps show where Max Parmar may publish in the future.

Co-authorship network of co-authors of Max Parmar

This figure shows the co-authorship network connecting the top 25 collaborators of Max Parmar. A scholar is included among the top collaborators of Max Parmar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Max Parmar. Max Parmar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Parmar, Max, et al.. (2025). The Relationship between Balance and Mobility in Poststroke Survivors: A Narrative Review. 9(1). 7–13. 1 indexed citations
3.
Murphy, Laura, Macey L. Murray, Louise Brown, et al.. (2023). 1782P Prostate radiotherapy reduces long-term risk of obstructive uropathy in metastatic hormone sensitive prostate cancer (mHSPC): Results from the STAMPEDE M1|RT comparison. Annals of Oncology. 34. S963–S963. 4 indexed citations
4.
Abdel‐Aty, Hassan, Laura E. O’Shea, Claire Amos, et al.. (2023). The STAMPEDE2 Trial: a Site Survey of Current Patterns of Care, Access to Imaging and Treatment of Metastatic Prostate Cancer. Clinical Oncology. 35(10). e628–e635. 4 indexed citations
5.
6.
7.
Kalsi, Jatinderpal, Andy Ryan, Aleksandra Gentry‐Maharaj, et al.. (2021). Completeness and accuracy of national cancer and death registration for outcome ascertainment in trials—an ovarian cancer exemplar. Trials. 22(1). 88–88. 8 indexed citations
8.
9.
Gentry‐Maharaj, Aleksandra, Oleg Blyuss, Andy Ryan, et al.. (2020). Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers. 12(7). 1931–1931. 22 indexed citations
10.
Karpinskyj, Chloe, Matthew Burnell, Arturo González-Izquierdo, et al.. (2020). Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics. 10(2). 89–89. 7 indexed citations
11.
Gilbert, Duncan C., Trinh Duong, Matthew R. Sydes, et al.. (2018). Transdermal oestradiol as a method of androgen suppression for prostate cancer within the STAMPEDE trial platform. British Journal of Urology. 121(5). 680–683. 15 indexed citations
12.
Grieve, Richard, Keith R. Abrams, Karl Claxton, et al.. (2016). Cancer Drugs Fund requires further reform : Reliance on “real world” observational data undermines evidence base for clinical practice. White Rose Research Online (University of Leeds, The University of Sheffield, University of York). 1 indexed citations
13.
Bailey, Katharine, Andy Ryan, Sophia Apostolidou, et al.. (2015). Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health. 15(1). 253–253. 12 indexed citations
14.
Vale, Claire L., Larysa Rydzewska, Jayne F. Tierney, et al.. (2015). 20LBA What is the current evidence for adding docetaxel or bisphosphonates to androgen deprivation therapy (ADT) in men with hormone sensitive prostate cancer? A systematic review and meta-analyses. European Journal of Cancer. 51. S719–S720. 3 indexed citations
15.
Abdel‐Rahman, Manar E., J. Butler, Matthew R. Sydes, et al.. (2014). No socioeconomic inequalities in ovarian cancer survival within two randomised clinical trials. British Journal of Cancer. 111(3). 589–597. 13 indexed citations
16.
Trimble, Edward L., Jeffrey S. Abrams, Ralph M. Meyer, et al.. (2009). Improving Cancer Outcomes Through International Collaboration in Academic Cancer Treatment Trials. Journal of Clinical Oncology. 27(30). 5109–5114. 35 indexed citations
17.
Burdett, Sarah, RJ Stephens, Lesley Stewart, et al.. (2008). Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group. Journal of Clinical Oncology. 26(28). 4617–4625. 165 indexed citations
18.
James, Nicholas D., Malcolm D. Mason, Matthew R. Sydes, et al.. (2007). 4027 POSTER Results of the feasibility stage of STAMPEDE: a Multi-Arm, Multi-Stage phase II/III trial in patients with high risk prostate cancer (MRC PR08, ISRCTN78818544). European Journal of Cancer Supplements. 5(4). 287–288. 1 indexed citations
19.
Tibaldi, Fabián, José Cortiñas Abrahantes, Geert Molenberghs, et al.. (2003). Simplified hierarchical linear models for the evaluation of surrogate endpoints. Journal of Statistical Computation and Simulation. 73(9). 643–658. 33 indexed citations
20.
Bailey, A.J., Max Parmar, & RJ Stephens. (1997). 794 Quality of life (QoL) in the chart randomised trial in non-small cell lung cancer (NSCLC): Short and long-term patient reported symptoms. Lung Cancer. 18. 205–205. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A Stone Breakdown of academic impact, for papers by Robin Schaffar Breakdown of academic impact, for papers by Sennett K. Kim Breakdown of academic impact, for papers by Jacopo Giuliani Breakdown of academic impact, for papers by Ragheed Al-Mufti Breakdown of academic impact, for papers by Melissa D. Curtis Breakdown of academic impact, for papers by Elizabeth L. Strevel Breakdown of academic impact, for papers by Paul You Breakdown of academic impact, for papers by Carmela Caballero Breakdown of academic impact, for papers by Rachel Dear
Rankless by CCL
2026